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ASP per therapy. RESULTS: Annual net reimbursement revenues per patient based 
on 340B acquisition costs were projected to be $53,270 for dabrafenib+trametinib 
combination, $27,043 for vemurafenib, $22,634 for dabrafenib, and $19,029 for 
trametinib. CONCLUSIONS: The addition of user-modifiable projected reimburse-
ment revenue calculation is a valuable tool that expands the contribution of eco-
nomic modeling to hospital formulary decision-making.
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OBJECTIVES: Strategies for screening incident colorectal cancers(CRC) for possible 
Lynch syndrome(LS) are evolving rapidly. Our objective is to compare the diagnos-
tic results and costs from two strategies for LS screening: Targeted Screening(TS) 
and Universal Screening(US) of tumors for mismatch repair(MMR) abnormali-
ties. METHODS: For 18-months in 2010-2011, we employed TS - individuals under 
60 years old and those meeting Bethesda criteria for LS. In 2012, we began US of all 
CRC. Immuno-histochemical(IHC) staining for the four MMR proteins was done in all 
cases. Microsatellite instability, BRAF mutation, MLH1 promoter methylation testing, 
and/or genetic testing of germ line DNA were done in selected cases. We modeled 
the diagnostic costs of several strategies for detecting LS, and the downstream costs 
of prevention CRC through colonoscopy screening, using a system dynamics model, 
built in the “Anylogic” program. RESULTS: In 2010-2011, 51 of 175 (29%) incident 
CRCs were screened by IHC using TS strategy; 15(29%) showed abnormal loss of 
> 1 MMR protein. Germ line MMR gene mutations were found in 4 cases and were 
suspected but not demonstrated in 11 additional cases. In 2012-2013, 194 CRCs were 
screened by IHC using US; 13(6.7%) of CRCs had abnormal staining suspicious for 
LS. MMR mutations were found in only 2/9 cases abnormal for IHC. Cost to identify 
the LS probands was ~$8,339/LS case diagnosed for targeted screening (four muta-
tion carriers/18 months) and ~$32,708/LS case diagnosed for universal screening 
(two mutation carriers/24 months). CONCLUSIONS: Real-world results were more 
complicated than anticipated. Results from US with IHC were often atypical, not 
diagnostic of LS. Economic analysis using our costs suggests that TS is less costly 
than US, but it will miss some cases of mildly penetrant LS. US identifies changes 
that are currently of unknown significance but that have potential to contribute to 
future research into the mechanisms of CRC tumorigenesis.
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OBJECTIVES: Little is known about cancer (CA) in hospitalization, cost and out-
comes in transitional countries. We studied this in a multicentric hospital study 
in Argentina. METHODS: Adult CA, hospital direct costs, re-admissions (ReH < 30 
days) and deaths in 1 yr output of 3 academic hospitals. Cost and results, harmo-
nized according HCUPS (USA) terminology groupers, of primary (1Dx), and second-
ary diagnosis (2Dx) for each CCS code (Clinical Classification Software-CCS single 
level-SL, 2009). Total costs (CT$), mean costs (SD) and median per discharge cost 
($, 25P-75P-percentiles), in Itl.$ PPP, (UN Data: 1Arg$ = 1.608 PPP, 2008). CA defined 
as (#CCS [descriptive term]), including from CCS #11 [head and neck CA] to #44 
[Neoplasms of unspecified nature or uncertain behavior] and CCS 45 [Maintenance 
chemotherapy; radiotherapy--QT;RT]. Readmisions (ReH) < 30 days and hospital 
deaths were obtained. RESULTS: Among 45 466 ≥ 19 yrs.old, CA was found in 6 
282, 13,81%(95%CI 13,50-14,14) Dx1; CCS 11-45 (F= 49,33%) (individual CA data not 
shown) while QT;RT (# 45) = 2 520 disch., 5,54% (4,75-5,15). Among CCS 45 [QT;RT] en 
1Dx, CCS #11-44 in any 2Dx up to 5 2Dx code adds 3,046 disch; adding CA codes 1Dx 
+2Dx = 9.298 discharges (20,45%, 20,08-20,82). Among CCS en 1Dx, CT $ = I $ PPP 64 
088 727; mean: I$ 17,035; SD: I$ 4,276; median: I$ 8,897 (25P 4,042; 75 P 19,601). ReH 
< 30 d = 485 (1,06 %, 0.97-1,16); while QT-RT (#45) ReH< 30 = 1,754 (3,86%, 3,68-4,04). 
Case fatality rate for CCS 11-44 was 3,27%,(2,86-3,74), and for CCS 45 was 0,17%,( 
0,06-0,45). CONCLUSIONS: CA burden among hospital discharges, and its costs, case 
fatality, and readmisions were obtained for the first time in Argentina. QT-RT as a 
first Dx is close to half of discharges, and showing CA en 2Dx behaves differently in 
ReH and mortality. An iceberg phenomenon of CA in 2Dx emerges.
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OBJECTIVES: Real-world data may inform decisions regarding treatment for renal 
cell carcinoma (RCC). We compared treatment persistence and healthcare costs for 
sunitinib and pazopanib, considering dosing cycle differences’ effect on days sup-
ply. METHODS: This retrospective cohort study used the Truven Marketscan® data-
base. Inclusion criteria were RCC diagnoses, age ≥ 20 years, ≥ 1 (index) prescription 
for sunitinib or pazopanib 10/1/2009 – 9/30/2013, and continuous plan enrollment ≥ 6 
months before to 12 months after index. We compared demographic and clinical char-
acteristics and treatment patterns, using Chi-square, Student t-test, and Wilcoxon 
signed-rank test (α = 0.05). Costs were compared using generalized linear modeling 
to adjust for demographic, clinical, and medication variables. Sensitivity analysis 
assessed effects of imputing days supply for sunitinib’s 42-day dosing for prescrip-
tions with 28 or 30 days supply. RESULTS: Among 466 patients (77% receiving suni-
tinib), the cohorts were not significantly (NS) different in demographics or Charlson 
Comorbidity Index. More sunitinib patients (46 vs. 6 pazopanib patients; p= 0.038) had 
of public healthcare in Ecuador to predict the financial consequences of introducing 
axitinib as a second line treatment in Ecuador. METHODS: Using a budget Impact 
analysis model, we estimated the incremental impact in the Ministry of public 
healthcare budget in Ecuador with the introduction of axitinib as treatment for 
mRCC in whom have failed the first line treatment. The comparative used drugs 
were sorafenib, everolimus, sunitinib, pazopanib and bevacizumab + IFNa. The epi-
demiological data was taken from GLOBOCAN 2012. The costs information 2014 was 
obtained from public sources and the model was built in Microsoft Excel 2007. The 
economic analysis is based in the incidence of RCC: metastatic, non-metastatic 
and the percentage of the patients with progression. The model considers two sce-
narios: 1) The current market of treatment without Axitinib, 2) The current market 
adding Axitinib. RESULTS: Based on the incidence of RCC and the Ecuador popula-
tion, we calculated 269 incident cases of RCC, 211 with metastatic disease and 58 
who will progress to metastatic disease, 97 patients received a first line treatment 
of whom 40.91% (40 patients) needed a 2ndline treatment. Along a 3 year follow-
up in the scenario were axitinib was added, the estimated cost was $5,810,416.84 
USD, with an incremental change of $26,098.99 USD and an incremental cost for 
the population with access to the national healthcare system of $0.00010 USD p/
month. CONCLUSIONS: The addition of axitinib as a second line treatment for 
mRCC had a minimal impact on the budget designated to the Ministry of public 
healthcare in Ecuador, and since it has an A1 recommendation level, it will represent 
an improvement in the mRCC treatment options.
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OBJECTIVES: Prostate cancer is the second leading cause of cancer death in 
American men and has a high economic burden. Enzalutamide received FDA 
approval for an expanded indication based on significant improvement in overall 
survival and radiographic progression-free survival in chemotherapy-naïve meta-
static castration-resistant prostate cancer (mCRPC) patients. Our objective was to 
estimate the 1-year budget impact (BI) of adopting enzalutamide’s expanded indica-
tion. METHODS: Epidemiologic data, including SEER incidence rates, were used to 
estimate total number of chemotherapy-naïve mCRPC patients in a hypothetical 
1-million member U.S. health plan. Treatment options included abiraterone acetate, 
sipuleucel-T, radium-223 dichloride, and docetaxel. Dosing, administration, mean 
duration of therapy and adverse event (AE) rates were based on package inserts 
and pivotal studies. Drug costs (including pre- and concomitant medications) were 
obtained from RedBook and CMS ASP pricing files, administration and monitoring 
from CMS Physician Fee Schedule, and AEs from AHRQ H-CUP and published litera-
ture. Drug utilization was estimated for each comparator before and after adoption 
of enzalutamide. Incremental aggregate budget, per patient per year (PPPY), per 
patient per month (PPPM), and per member per month (PMPM) impact were cal-
culated. One-way sensitivity analyses were performed. RESULTS: In an estimated 
population of 115 mCRPC patients, adopting the new enzalutamide indication 
had modest annual plan impact ($510,641 incremental aggregate BI, $4,426 PPPY, 
$368.83 PPPM and $0.04 PMPM). Enzalutamide acquisition cost was partially offset 
by moderate AEs and no additional monitoring costs. Results were most sensitive 
to enzalutamide drug cost, size of chemotherapy-naïve mCRPC patient population 
and enzalutamide adoption rate. CONCLUSIONS: Results indicate a modest 1-year 
BI to adopt enzalutamide for chemotherapy-naïve mCRPC patients, partly due to the 
cost offset of moderate incidence of AEs and lack of additional required monitoring. 
Further analysis to understand cost per clinical outcome may complement the BI 
model to understand relative costs and benefits.
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OBJECTIVES: Economic modeling is an accepted tool for making formulary decisions 
by payers in the US. Hospital and institutional healthcare providers have expressed 
increased interest in using economic modeling in their decision making processes, 
particularly regarding potential reimbursement based on hospital-specific pricing. 
This study presents hospital perspective results from a revenue impact (RI) calcula-
tor component of an economic model. METHODS: An economic model was devel-
oped that investigated the RI (pharmaceutical acquisition costs minus projected 
reimbursement) of introducing National Comprehensive Cancer Network Category 1 
recommended therapies for BRAF V600 mutated metastatic melanoma to a hospital 
formulary. Therapies investigated in the analysis included: dabrafenib+trametinib 
combination therapy, vemurafenib monotherapy, dabrafenib monotherapy, and 
trametinib monotherapy. The model calculated the annual pharmaceutical acqui-
sition cost of each therapy based on recommended dosing, progression-free survival 
as a marker for duration of treatment, and drug pricing. Pricing data was retrieved 
from the Truven Health Analytics RED BOOK™ database. Acquisition costs in the 
model could be set to 340B, wholesale acquisition cost (WAC), or average wholesale 
price (AWP) values. The model used a default 30% discount compared to WAC to 
approximate 340B pricing. The projected reimbursement in the model uses WAC 
plus a modifiable 4.3% (based on the Medicare permitted reimbursement premium) 
for both Medicare and commercial payers. The perspective payer mix and respec-
tive reimbursement percentages can be modified by the model user. WAC was used 
in place of average sales price (ASP) due to the unavailability of hospital-specific 
